Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $17 from $13 and keeps an Overweight rating on the shares following the Q2 report. The firm believes the shares are undervalued on the core business but that Sotera’s litigation overhang limits what investors are willing to pay.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: